About the Company
intra-cellular therapies is a company based out of 3960 broadway, new york, new york, united states.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $ITCI News
Intra-Cellular Therapies Is On Fire
Intra-Cellular Therapies' flagship drug, CAPLYTA, shows potential to treat Major Depressive Disorder. Read why I rate ITCI ...
Buy Rating Affirmed for Intra-Cellular Therapies Amid Positive Outlook for Caplyta’s MDD Trial
Begin your TipRanks Premium journey today. Intra-Cellular Therapies (ITCI) Company Description: Intra-Cellular Therapies, Inc. is a biopharmaceutical company, which focuses on the discovery and ...
Intra-Cellular Therapies Inc Chairman, President & CEO Sharon Mates Sells 61,277 Shares
Sharon Mates, Chairman, President & CEO of Intra-Cellular Therapies Inc (NASDAQ:ITCI), sold 61,277 shares of the company on ...
Intra-Cellular Therapies to Participate in Three Upcoming Investor Conferences
NEW YORK, March 06, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company ...
11 Best Small Cap Pharma Stocks to Invest In
For pharma stocks, these can be either big ticket and stable names such as Pfizer Inc. (NYSE:PFE) and Johnson & Johnson (NYSE ...
ITCI Apr 2024 90.000 call
Sharon Mates, Chairman, President & CEO of Intra-Cellular Therapies Inc (NASDAQ:ITCI), sold 61,277 shares of the company on March 11, 2024, according to a recent SEC Filing. NEW YORK, March 06, 2024 ...
Analysts Are Bullish on These Healthcare Stocks: 2seventy bio (TSVT), Immuneering (IMRX)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on 2seventy bio (TSVT – Research Report) and ...
100 Stocks You Should Have Invested In 5 Years Ago
If you know even a little bit about finance and investing, then you probably know that the stock market offers the most ...
Cellular Highways’ fastest cell sorter in the world takes Highway1 to success
Cellular Highways has launched Highway1, its cell sorting tool, which can singulate 43,000 cells per second, making it the ...
Asgard Therapeutics announces €30 million Series A…
The round was co-led by RV Invest and Johnson & Johnson Innovation – JJDC, Inc., with ... in vivo cellular reprogramming in oncology. We’re proud to continue to support Asgard in its mission to bring ...
Asgard Therapeutics announces €30 million Series A financing to advance its first-in-class in vivo cell reprogramming platform for immuno-oncology
Co-led by RV Invest and Johnson & Johnson Innovation - JJDC, Inc. with participation from existing investors Novo Holdings, Boehringer Ingelheim Venture Fund and IndustrifondenLead program is ...
Loading the latest forecasts...